{ "docId": "019dd923-5ca1-7489-b639-45501f4b359b", "docSlug": "158df8627a0b9aca", "documentTitle": "Opioid Conflicts Majority Staff Report", "authorId": "McKinsey", "authorName": "U.S. House Committee on Oversight and Reform", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "portrait", "aspectRatio": 0.773, "pageNumber": 13, "pageCount": 53, "prevPage": 12, "nextPage": 14, "slideType": "appendix_disclosure", "function": "cite_precedent", "density": "overcrowded", "nDataPoints": 0, "notes": "This appears to be a page from a formal investigative report or legal document.", "elementsJson": [ "paragraph", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/13", "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b", "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json", "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-13", "components": [ { "bbox": null, "kind": "callout", "text": "The Committee has identified an additional 19 McKinsey consultants, in addition to the three above, who performed work for both FDA and opioid manufacturers.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd951-cdec-74db-b499-ddd03dbdc196", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.78, "x": 0.11, "y": 0.272 }, "kind": "paragraph", "text": "In July 2018, Mr. Ghatak and another McKinsey Senior partner, Martin Elling, discussed destroying documents relating to their work at Purdue. In February 2021, McKinsey stated that it had fired both Mr. Ghatak and Mr. Elling.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "0c64fd0e-36d3-4cca-a4c5-8f58e937d6a9", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.78, "x": 0.11, "y": 0.376 }, "kind": "paragraph", "text": "The Committee has identified an additional 19 McKinsey consultants, in addition to the three above, who performed work for both FDA and opioid manufacturers. Documents obtained by the Committee suggest a pattern of assigning the same consultants to work on McKinsey’s projects for FDA and opioid clients. Two of the consultants identified by the Committee as having worked for both FDA and opioid manufacturers currently serve at the highest levels of the firm, with one sitting on McKinsey’s Client Service Risk Committee and the other on the firm’s Shareholders Council, McKinsey’s equivalent of a board of directors.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "265609e8-f369-4285-ad22-202e172aff15", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.78, "x": 0.11, "y": 0.515 }, "kind": "paragraph", "text": "Three of these additional McKinsey consultants—all McKinsey partners—are discussed below.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "601d9ace-f0af-4404-a8bc-b14a06edd594", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.78, "x": 0.11, "y": 0.603 }, "kind": "paragraph", "text": "Former McKinsey consultant Ted Fuhr worked on five FDA contracts between May 2010 and February 2014 before working on five projects at Purdue Pharma. While working on FDA contracts, Mr. Fuhr appears to have also unofficially consulted on matters related to Purdue. For instance, on May 5, 2010, Mr. Fuhr started an FDA contract “to assist FDA in evaluating existing global product safety efforts and developing and implementing the Global Product", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "790fcc00-66d9-40b8-b955-06786f003f12", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.78, "x": 0.11, "y": 0.115 }, "kind": "paragraph", "text": "Mr. Ghatak also consulted for other opioid manufacturers. A 2011 McKinsey presentation stated that he would provide “senior counsel” on a project to “turbocharge” Nucynta, a Johnson & Johnson opioid. In 2015, he appears to have helped implement McKinsey’s strategy for Endo International’s “Sales Force Blitz” of its opioid products.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "e450826e-abf3-44de-8497-c369dd71e872", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.78, "x": 0.11, "y": 0.202 }, "kind": "paragraph", "text": "As described below, in January 2018, Mr. Ghatak contributed to a McKinsey-generated transition memo on the opioid crisis that had been prepared for incoming HHS Secretary Alex Azar, despite consulting for Purdue at the time.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "eecb533e-40ae-47ae-8933-0f310aa1a9a2", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.1, "w": 0.78, "x": 0.11, "y": 0.725 }, "kind": "source-note", "text": "40 MCK-HCOR-0202077; MCK-HCOR-0202079, Slide 4. 41 MCK-HCOR-0274099; MCK-HCOR-0297705. 42 MCK-HCOR-0179910. 43 MCK-HCOR-0173795. 44 States Pressure Drugmakers After McKinsey’s $600 Million Opioid Settlement, Wall Street Journal (Feb. 4, 2021). 45 MCK-HCOR-0355686 to MCK-HCOR-0355698 (McKinsey FDA Engagement List); MCK-HCOR-0356043 to MCK-HCOR-0356048 (McKinsey FDA Supplemental Consultant List).", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7740ab93-c528-4760-a9c7-f6b0f15af481", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.56, "x": 0.22, "y": 0.345 }, "kind": "title", "text": "2. Additional Cross-Over of Consultants", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "84396d30-c874-40b6-9f99-bf88fd13ae50", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.1, "x": 0.11, "y": 0.568 }, "kind": "title", "text": "Ted Fuhr", "attrs": null, "subkind": "subtitle", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "53576b34-aec7-46c8-990d-563c92f20728", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 28, "from": 6, "beatId": "ca9c3ab4-903c-4ff0-b53d-42335d2ce596", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents extensive evidence of McKinsey's conflicts of interest, including consultant overlaps and contract details.", "position": 1, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "loops": [ { "to": 53, "from": 1, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033", "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.", "position": 0, "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }